Online inquiry

IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2881MR)

This product GTTS-WQ2881MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CCR4 gene. The antibody can be applied in Tropical spastic paraparesis, Adult T cell leukemia/lymphoma (ATL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005508.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1233
UniProt ID P51679
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2881MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10536MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ6472MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CT-P-59
GTTS-WQ1479MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ15943MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ12250MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ2462MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 181
GTTS-WQ8418MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ4043MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI 655130
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW